Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Financing Activities (2023 - 2025)

NewAmsterdam Pharma's Cash from Financing Activities history spans 3 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 97.0% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $29.5 million, down 95.52%, while the annual FY2025 figure was $29.5 million, 95.52% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $13.7 million at NewAmsterdam Pharma, up from $5.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $456.6 million in Q4 2024 and bottomed at $58000.0 in Q3 2024.
  • The 3-year median for Cash from Financing Activities is $5.9 million (2025), against an average of $63.4 million.
  • The largest YoY upside for Cash from Financing Activities was 10058.62% in 2025 against a maximum downside of 97.0% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $186000.0 in 2023, then surged by 245389.78% to $456.6 million in 2024, then plummeted by 97.0% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Cash from Financing Activities are $13.7 million (Q4 2025), $5.9 million (Q3 2025), and $3.4 million (Q2 2025).